{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:43:13Z","timestamp":1794717793730,"version":"4.9.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Up to 70%-80% of patients with primary sclerosing cholangitis (PSC) will have concomitant inflammatory bowel disease (IBD). Scarce data are available regarding outcomes of advanced therapies to treat IBD-PSC. We performed a systematic review and meta-analysis to assess the effectiveness and safety of advanced therapies in IBD-PSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in Cochrane Library, Embase, Google Scholar, Ovid Medline, PubMed, Scopus, and Web of Science from database inception to January 29, 2025. We included studies that reported on IBD clinical response with advanced therapies. Meta-analysis was performed using the random effects model. Subgroup analyses were conducted to further investigate proportion differences between covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen studies (n\u2009=\u2009864) were included in the final analysis. Among IBD-PSC patients treated with advanced therapies, clinical response was observed in 52% (95% CI, 40%-65%; I2\u2009=\u200985%), clinical remission in 43% (95% CI, 25%-62%; I2\u2009=\u200991%), and endoscopic remission in 26% (95% CI, 13%-42%; I2\u2009=\u200975%). Infections occurred in 22% of patients (95% CI, 8%-40%; I2\u2009=\u200982%) and acute cholangitis was observed in 14% of patients (95% CI, 2%-33%; I2\u2009=\u200980%). The endoscopic remission rate with anti-tumor necrosis factor (anti-TNF) agents was 29% (95% CI, 10%-52%; I2\u2009=\u200928%) vs. 15% (95% CI, 4%-29%; I2\u2009=\u200970%) in those who received non-anti-TNF biologics. The rates of overall infections were similar in patients who received anti-TNF vs. non-anti-TNF biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Advanced therapies show efficacy and comparable safety in IBD-PSC. The study findings are limited by significant heterogeneity and further prospective studies with standardized endpoints are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag001","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T12:34:02Z","timestamp":1768134842000},"page":"1366-1375","source":"Crossref","is-referenced-by-count":4,"title":["Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1983-0165","authenticated-orcid":false,"given":"Darrick K","family":"Li","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Chaar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Arabi","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University , Riyadh,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health , Abu Dhabi,","place":["United Arab Emirates"]},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology , Abu Dhabi,","place":["United Arab Emirates"]},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham , Birmingham,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elgamal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Alahdab","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Biostatistics, Medical Epidemiology, University of Missouri , Columbia, MO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-0056","authenticated-orcid":false,"given":"Alyssa A","family":"Grimshaw","sequence":"additional","affiliation":[{"name":"Harvey Cushing\/John Hay Whitney Medical Library, Yale University , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-9267","authenticated-orcid":false,"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"College of Medicine, Alfaisal University , Riyadh,","place":["Saudi Arabia"]},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, King Faisal Specialist Hospital , Riyadh,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026070620124095500_izag001-B1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"2026070620124095500_izag001-B2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.gastro.2016.08.046","article-title":"Shifting paradigms: what is the true prevalence and clinical course of primary sclerosing cholangitis?","volume":"151","author":"Weersma","year":"2016","journal-title":"Gastroenterology"},{"key":"2026070620124095500_izag001-B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC phenotypes of PSC-IBD","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"2026070620124095500_izag001-B4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","author":"European Association for the Study of the Liver (EASL)","year":"2022","journal-title":"J Hepatol"},{"key":"2026070620124095500_izag001-B5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"2026070620124095500_izag001-B6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17474124.2022.2031979","article-title":"PSC associated inflammatory bowel disease: a distinct entity","volume":"16","author":"Beheshti-Maal","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"2026070620124095500_izag001-B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1067\/mge.2002.125367","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis","volume":"56","author":"Soetikno","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"2026070620124095500_izag001-B9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/liv.13548","article-title":"Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011","volume":"38","author":"S\u00f8rensen","year":"2018","journal-title":"Liver Int"},{"key":"2026070620124095500_izag001-B11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MEG.0000000000002510","article-title":"Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"35","author":"Sayed","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B12","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000347","article-title":"Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"8","author":"Shah","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026070620124095500_izag001-B13","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026070620124095500_izag001-B14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026070620124095500_izag001-B15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/jrsm.1563","article-title":"Citationchaser: a tool for transparent and efficient forward and backward \u00adcitation chasing in systematic searching","volume":"13","author":"Haddaway","year":"2022","journal-title":"Res Synth Methods"},{"key":"2026070620124095500_izag001-B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"2026070620124095500_izag001-B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2026070620124095500_izag001-B18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2026070620124095500_izag001-B19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026070620124095500_izag001-B20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2026070620124095500_izag001-B21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620124095500_izag001-B22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12876-021-01883-6","article-title":"Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFalpha in inflammatory bowel disease","volume":"21","author":"Alipour","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2026070620124095500_izag001-B23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2026070620124095500_izag001-B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620124095500_izag001-B25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/apt.17386","article-title":"Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis","volume":"57","author":"Taxonera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620124095500_izag001-B26","doi-asserted-by":"publisher","author":"Gracie DJ, Williams CJM, Sood R et al.","DOI":"10.1038\/ajg.2016.59"},{"key":"2026070620124095500_izag001-B27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal \u00adcolon","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B29","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1007\/s10620-013-2697-7","article-title":"The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis","volume":"58","author":"Schaeffer","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026070620124095500_izag001-B30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American gastroenterological association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"2026070620124095500_izag001-B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J Hepatol"},{"key":"2026070620124095500_izag001-B33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/lt.23587","article-title":"Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis","volume":"19","author":"Goldberg","year":"2013","journal-title":"Liver Transpl"},{"key":"2026070620124095500_izag001-B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000573","article-title":"Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study","volume":"8","author":"Irving","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"2026070620124095500_izag001-B35","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026070620124095500_izag001-B36","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620124095500_izag001-B37","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/ecco-jcc\/jjx057","article-title":"Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis","volume":"11","author":"Westerouen van Meeteren","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026070620124095500_izag001-B38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ibd\/izad108","article-title":"Safety of biologic and small molecule therapy for inflammatory bowel disease among solid organ transplant recipients: systematic review and meta-analysis","volume":"30","author":"Taneja","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620124095500_izag001-B39","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/2050640619858050","article-title":"Safety of vedolizumab in liver transplant recipients: a systematic review","volume":"7","author":"Spadaccini","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2026070620124095500_izag001-B40","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.semarthrit.2021.08.013","article-title":"Safety of biologic treatments in solid organ transplant recipients: a systematic review","volume":"51","author":"Meyer","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026070620124095500_izag001-B41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026070620124095500_izag001-B42","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing \u00adcholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620124095500_izag001-B44","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.14309\/01.ajg.0000860460.33213.97","article-title":"S955\u2003Effectiveness of vedolizumab in patients with inflammatory bowel disease and concomitant primary sclerosing cholangitis","volume":"117","author":"Santiago","year":"2022","journal-title":"Am J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1366\/66864140\/izag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1366\/66864140\/izag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:12:46Z","timestamp":1783383166000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/7\/1366\/8475252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag001","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,12]]}}}